touchEXPERT OPINIONS Improving patient outcomes in moderate-to-severe ulcerative colitis
Watch leading experts discuss important considerations in the optimal management of patients with moderate-to-severe ulcerative colitis.
What is the significance of the disease burden of ulcerative colitis when assessing patients?
Prof. Hart discusses the significant burden that ulcerative colitis places on patients both clinically and psychosocially, which should be proactively managed as part of a patient-centred care approach to improve overall quality of life.
1/3 Next InterviewIn this interview Prof. Ailsa Hart answers the following questions:
- How does a diagnosis of ulcerative colitis impact patients’ lives?
- How can we assess and treat the full impact of ulcerative colitis on patients in clinical practice?
- How do current treatment options impact quality of life for patients with moderate-to-severe ulcerative colitis, and how should challenging symptoms be managed?
Ailsa Hart is Consultant Gastroenterologist at St Mark’s Hospital and Dean of St Mark’s Hospital Academic Institute, London, UK. read more
In 2016, she achieved academic promotion at Imperial College London, UK, and is now Professor of Practice. She is also Honorary Skou Professor at the University of Aarhus in Denmark. She studied medicine at Oxford University and was awarded a First-Class Honours degree. She achieved her PhD with Imperial College London, funded by a Wellcome Trust Fellowship.
Prof. Hart has mentored and trained many gastroenterologists, who are now clinical investigators engaged in inflammatory bowel disease (IBD) research nationally and internationally. Together with many of them, she has published two books and over 250 papers, reviews and book chapters. She is currently on the governing board of the European Crohn’s and Colitis Organisation (ECCO) as scientific officer and was past treasurer and member of the Clinical Committee of ECCO. She is on the IBD Clinical Research Group Committee for the British Society of Gastroenterology (BSG) and is past chair of the Gut Microbiota for Health Group of the BSG. She is the UK patient and public involvement lead for gastroenterology and is on the research committee for the Crohn’s and Colitis UK charity. She is a member of the International Organization for the Study of Inflammatory Bowel Disease.
Prof. Ailsa Hart discloses: Advisory board or panel fees from AbbVie, Bristol Myers Squibb, Dr Falk Pharma, Janssen, Merck Sharp & Dohme, Pfizer, Roche and Takeda.
The importance of timely diagnosis and early treatment in ulcerative colitis: Why does it matter?
Dr Melmed discusses why a timely diagnosis and early treatment in ulcerative colitis is so important including the potentially progressive nature of the disease, prognostic risk factors, current treatments for moderate-to-severe vs mild ulcerative colitis, and therapeutic drug monitoring as a useful approach for optimal management.
2/3 Next InterviewIn this interview Dr Gil Melmed answers the following questions:
- When considering early diagnosis and treatment in ulcerative colitis, what can we learn from Crohn’s disease?
- What do we need to evaluate to ensure ulcerative colitis is diagnosed and treated at an early stage?
- How does the treatment of moderate-to-severe disease differ compared with mild disease?
- How can we further improve outcomes for patients with moderate-to-severe ulcerative colitis?
Gil Y Melmed, MD, MS, is Co-director of the Inflammatory Bowel Disease Center at Cedars-Sinai Medical Center in Los Angeles, California, USA. He earned his medical degree from Albert Einstein College of Medicine in the Bronx, New York, and master of science in clinical research from UCLA School of Medicine, Los Angeles. He completed his gastroenterology fellowship at the University of California, Los Angeles. read more
Dr Melmed has authored or co-authored more than 150 articles in peer-reviewed journals and several book chapters. Dr Melmed has served as associate editor of the American Journal of Gastroenterology, and clinical research editor for Inflammatory Bowel Disease. His interests include clinical outcomes and quality of care in inflammatory bowel disease (IBD), as well as translational prognostic and therapeutic strategies to improve inflammation and clinical outcomes. He has led or participated in the development of quality indicators for IBD with the American Gastroenterology Association, the Crohn’s and Colitis Foundation, the National Quality Forum, and the Canadian Crohn’s and Colitis organizations.
Dr Gil Melmed discloses: Consultancy fees from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Ferring, Janssen, Medtronic, Oshi, Pfizer, Samsung Bioepis, Shield Therapeutics, Takeda and Techlab; Grants/research support from Pfizer; Other financial or material support (royalties, patent, etc.) from Aytu Biosciences; and Stocks/shares (self-managed) from Nephroceuticals.
How might emerging therapy options in ulcerative colitis impact current clinical practice?
Prof. Feagan discusses the primary considerations for the development of new therapies for the treatment of moderate-to-severe ulcerative colitis, and the emerging drug classes/therapeutic targets showing greatest potential. He shares his expert insight on how the changing treatment landscape may impact clinical practice.
3/3 Take CE/CME TestIn this interview Prof. Brian Feagan answers the following questions:
- When considering the current treatment landscape in ulcerative colitis, what are the key issues that emerging therapies should address?
- What are the targets currently under investigation for novel therapies in ulcerative colitis?
- What are the latest data for S1P receptor modulators in ulcerative colitis?
- What are the latest data for JAK inhibitors in ulcerative colitis?
- What are the latest data for other small molecules in ulcerative colitis?
- How do you think the landscape will change in the treatment of moderate-to-severe ulcerative colitis in the next 5–10 years?
Brian Feagan completed a medical degree at the University of Western Ontario (UWO) in London, Ontario, Canada. His postdoctoral training included a residency in internal medicine and a clinical fellowship in gastroenterology in the Department of Medicine at UWO, and postgraduate training in the Department of Epidemiology and Biostatistics at McMaster University, Hamilton, Ontario. read more
A fellow of the Royal College of Physicians and Surgeons of Canada, Prof. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada, and the European Crohn’s and Colitis Organization. He has authored over 480 articles and book chapters and has given over 600 invited presentations at national and international scientific meetings. In 1997, Prof. Feagan became Director of Robarts Clinical Trials at the Robarts Research Institute, UWO and in 2020, he became Senior Scientific Director of Alimentiv Inc. (formerly Robarts Clinical Trials). His research efforts focus on the design and implementation of randomized controlled trials of therapy for inflammatory bowel disease. He has been the principal investigator on numerous large-scale randomized clinical trials.
Prof. Brian Feagan discloses: Advisory board or panel fees from AbbVie, Amgen, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, EcoR1 Capital, Genentech/Roche, GlaxoSmithKline, InDex Pharmaceuticals, Janssen, Morphic Therapeutic, Novartis, Origo BioPharma, Pfizer, Progenity, Prometheus, Takeda, Teva and Tillotts Pharma; Consultancy fees from AbbVie, AdMIRx, AgomAb Therapeutics, Akebia Therapeutics, Alimentive Inc., Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport Inc., Arena Pharma, Avir, Azora Therapeutics, Boehringer Ingelheim, Celgene/BMS, Connect BioPharma, Cytoki, Everest Clinical Research Corp., Eli Lilly, Ferring, Galapagos, Galen Pharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Gossamer Pharma, Hoffmann-La Roche, InDex Pharmaceuticals, Intact Therapeutics, Janssen, Kaleido Biosciences, Millennium, Morphic Therapeutics, Mylan, Origo BioPharma, Pandion Therapeutics, Pfizer, Progenity, Prometheus Therapeutics and Diagnostics, PTM Therapeutics, Rebiotix, RedHill Biopharma, Sandoz, Sanofi, Seres Therapeutics, Surrozen Inc., Takeda, Teva, Thelium, Theravance, Tigenix, Tillotts Pharma, UCB Pharma, VHsquared Ltd, Viatris, Ysios and Zealand Pharma; Speaker bureau fees from AbbVie, Janssen and Takeda; and Stocks/shares (self-managed) from Gossamer Pharma.
Overview & Learning Objectives
Overview
In this activity, three experts consider aspects that are crucial to improving outcomes in patients with moderate-to-severe ulcerative colitis: the significance of disease burden when assessing patients; the importance of timely diagnosis and early treatment; and the potential of emerging treatment options.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of immunologists and gastroenterologists involved in the management of ulcerative colitis.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Prof. Ailsa Hart discloses: Advisory board or panel fees from AbbVie, Bristol Myers Squibb, Dr Falk Pharma, Janssen, Merck Sharp & Dohme, Pfizer, Roche and Takeda.
Dr Gil Melmed discloses: Consultancy fees from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Ferring, Janssen, Medtronic, Oshi, Pfizer, Samsung Bioepis, Shield Therapeutics, Takeda and Techlab; Grants/research support from Pfizer; Other financial or material support (royalties, patent, etc.) from Aytu Biosciences; and Stocks/shares (self-managed) from Nephroceuticals.
Prof. Brian Feagan discloses: Advisory board or panel fees from AbbVie, Amgen, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, EcoR1 Capital, Genentech/Roche, GlaxoSmithKline, InDex Pharmaceuticals, Janssen, Morphic Therapeutic, Novartis, Origo BioPharma, Pfizer, Progenity, Prometheus, Takeda, Teva and Tillotts Pharma; Consultancy fees from AbbVie, AdMIRx, AgomAb Therapeutics, Akebia Therapeutics, Alimentive Inc., Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport Inc., Arena Pharma, Avir, Azora Therapeutics, Boehringer Ingelheim, Celgene/BMS, Connect BioPharma, Cytoki, Everest Clinical Research Corp., Eli Lilly, Ferring, Galapagos, Galen Pharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Gossamer Pharma, Hoffmann-La Roche, InDex Pharmaceuticals, Intact Therapeutics, Janssen, Kaleido Biosciences, Millennium, Morphic Therapeutics, Mylan, Origo BioPharma, Pandion Therapeutics, Pfizer, Progenity, Prometheus Therapeutics and Diagnostics, PTM Therapeutics, Rebiotix, RedHill Biopharma, Sandoz, Sanofi, Seres Therapeutics, Surrozen Inc., Takeda, Teva, Thelium, Theravance, Tigenix, Tillotts Pharma, UCB Pharma, VHsquared Ltd, Viatris, Ysios and Zealand Pharma; Speaker bureau fees from AbbVie, Janssen and Takeda; and Stocks/shares (self-managed) from Gossamer Pharma.
Content reviewer
Patrick Brady, MD, has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Christina Mackins-Crabtree has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 13 April 2022. Date credits expire: 13 April 2023.
If you have any questions regarding credit please contact cpdsupport@usf.edu
Learning Objectives
After watching this activity, participants should be better able to:
- Describe the disease burden associated with ulcerative colitis and how it relates to patient management
- Recognize the importance of early diagnosis and describe treatment options in patients with moderate-to-severe ulcerative colitis
- Evaluate novel agents in development for the treatment of moderate-to-severe ulcerative colitis and consider how they may impact current clinical practice
Register to touchIMMUNOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights
